Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells

European Journal of Pharmacology

Volumn 367, Issue 2-3, 1999, Pages 413-422

  Fierens, Frederik ^a   Vanderheyden, Patrick M L ^a   De Backer, Jean Paul ^a   Vauquelin, Georges ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

3H Candesartan; Angiotensin II; Dissociation; Non peptide antagonist; Reassociation; Recovery

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; LOSARTAN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; INOSITOL PHOSPHATE; LIGAND; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; ANIMAL; COMPUTER SIMULATION; DRUG ANTAGONISM; FEMALE; GENETIC TRANSFECTION; GENETICS; HAMSTER; HUMAN; IN VITRO STUDY; METABOLISM; PROTEIN BINDING; TIME;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; FEMALE; HUMANS; INOSITOL PHOSPHATES; LIGANDS; LOSARTAN; PROTEIN BINDING; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TIME FACTORS; TRANSFECTION;

EID: 0032970721     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00965-0     Document Type: Article

References (27)

1. 1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane heIices III and VII. J. Biol. Chem. 272:1997;4245-4251.
2. Bumpus F.M., Catt K.J., Chiu A.T., DeGasparo M., Goodfriend T., Husain A., Peach M.J., Taylor D.G. Jr., Timmermans P.B. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension. 17:1991;720-721.
3. l subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 265:1993;826-834.
4. Chang R.S., Siegl P.K., Clineschmidt B.V., Mantlo N.B., Chakravarty P.K., Greenlee W.J., Patchett A.A., Lotti V.J. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 262:1992;133-138.
5. De Chaffoy de Courcelles D., Leysen J.E., Roevens P., Van Belle H. The serotonin-S2 receptor: a receptor, transducer coupling model to explain insurmountable antagonist effects. Drug Dev. Res. 8:1986;173-178.
6. Dickinson K.E., Cohen R.B., Skwish S., Delaney C.L., Serafino R.P., Poss M.A., Gu Z., Ryono D.E., Moreland S., Powell J.R. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br. J. Pharmacol. 113:1994;179-189.
7. Gero A. Desensitization, two-state receptors and pharmacological parameters. J. Theor. Biol. 103:1983;137-161.
8. Iwai N., Inagami T. Identification of two subtypes in the rat type I angiotensin II. FEBS Lett. 298:1992;257-260.
9. Kakar S.S., Sellers J.C., Devor D.C., Musgrove L.C., Neill J.D. Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem. Biophys. Res. Commun. 183:1992;1090-1096.
10. Kondo T., Yoshida K., Yoshimura Y., Motohashi M., Tanayama S. Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneim.-Forsch./Drug Res. 46:1996;594-600.
11. Kostenis E., Mohr K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol. Sci. 17:1996;280-283.
12. Liu Y.J., Shankley N.P., Welsh N.J., Black J.W. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and synoptic action. Br. J. Pharmacol. 106:1992;233-241.
13. Mochizuki S., Sato T., Furata K., Hase K., Ohkura Y., Fukai C., Kosakai K., Wakabayashi S., Tomiyama A. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J. Cardiovasc. Pharmacol. 25:1995;22-29.
14. Noda K., Saad Y., Karnik S.S. Interaction of Phe8 of angiotensin II with Lys199 and His256 of ATl receptor in agonist activation. J. Biol. Chem. 270:1995;28511-28514.
15. 1 receptor. Eur. J. Pharmacol. 319:1997;137-146.
16. Panek R.L., Lu G.H., Overhisser R.W., Major T.C., Hodges J.C., Taylor D.G. Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J. Pharmacol. Exp. Ther. 273:1995;753-761.
17. Perlman S., Schamby H.T., Rivero R.A., Greenlee W.J., Hjorth S.A., Schwartz T.W. Non-peptide angiotensin agonist. Functional and molecular interaction with the ATl receptor. J. Biol. Chem. 270:1995;1493-1496.
18. 1 receptor antagonist. Br. J. Pharmacol. 107:1992;1173-1180.
19. Robertson M.J., Dougall I.G., Harper D., Mckechnie K.C.W., Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol. Sci. 15:1994;364-369.
20. Seeuwen K., Lagarde A., Pouysségur J. Deregulation of hamster fibroblast proliferation by mutated ras oncogenes is not mediated by constitutive activation of phosphoinositide-specific phospholipase C. EMBO J. 7:1988;161-168.
21. Shibouta Y., Inada Y., Ojima M., Wada T., Noda M., Sanada T., Kubo K., Kohara Y., Naka T., Nishikawa K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-l-[[2.45-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7- carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxy-carbonyloxy)-ethyl2-ethoxy-1-[[2′-(1H- tetrazol-5-yl)biohenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J. Pharmacol. Exp. Ther. 266:1993;114-120.
22. Timmermans P.B.M.W.M., Wong P.C., Chiu A.T., Herblin W.F. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol. Sci. 12:1991;55-62.
23. Timmermans P.B.M.W.M., Benfield P., Chiu A.T., Herblin W.F., Wong P.C. Angiotensin II receptors and functional correlates. Am. J. Hypertens. 5:1992;221S-235S.
24. Vallotton M.B. The renin-angiotensin system. Trends. Pharmacol., Sci. 8:1987;69-74.
25. 1 receptors. Br. J. Pharmacol. (in press).
26. Wong P.C., Price A.W., Chiu A.T., Duncia J.V., Carini D.J., Wexler R., Johnson A., Timmermans P.B.M.W.M. Nonpepride angiotensin receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensice agent. J. Pharmacol. Exp. Ther. 255:1990;211-217.
27. Zhang J.C., Van Meel A., Pfaffendorf M., Van Zwieten P. Different types of angiotensin II receptor antagonism induced by BIBS 222 in the rat portal vein and rabbit aorta; the influence of receptor reserve. J. Pharmacol. Exp. Ther. 269:1993;509-514.